Alpha Cognition’s (ACOG) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Alpha Cognition (NASDAQ:ACOG) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Separately, Raymond James raised Alpha Cognition to a “moderate buy” rating in a report on Tuesday, March 25th.

Alpha Cognition Stock Performance

Shares of ACOG stock opened at $8.65 on Friday. The business’s 50-day moving average price is $5.44. The stock has a market capitalization of $138.57 million, a price-to-earnings ratio of -3.38 and a beta of 2.48. Alpha Cognition has a 1 year low of $3.75 and a 1 year high of $9.68.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.38.

Hedge Funds Weigh In On Alpha Cognition

A number of hedge funds and other institutional investors have recently made changes to their positions in ACOG. Rosalind Advisors Inc. purchased a new position in shares of Alpha Cognition during the fourth quarter worth about $1,489,000. National Bank of Canada FI purchased a new position in shares of Alpha Cognition during the fourth quarter worth about $69,000. Aristides Capital LLC purchased a new position in shares of Alpha Cognition during the fourth quarter worth about $1,178,000. ADAR1 Capital Management LLC purchased a new position in shares of Alpha Cognition during the fourth quarter worth about $1,204,000. Finally, Altium Capital Management LLC purchased a new position in shares of Alpha Cognition during the fourth quarter worth about $1,620,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.